Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.33 |
| ▸ | IL1B | P01584 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094539 | 0.84 | CA14 (0.32) | CA14IL1BP2RX7RORC | |
| SCHEMBL1845039 | 0.83 | SSTR4 (0.38) | SSTR4CA14OPRM1OPRD1 | |
| SCHEMBL27809300 | 0.78 | OPRM1 (0.35) | OPRM1OPRD1P2RX7RORC | |
| SCHEMBL19083254 | 0.76 | SLC6A1 (0.37) | SSTR4CA14 | |
| SCHEMBL1852468 | 0.75 | SSTR4 (0.36) | SSTR4CA14 | |
| SCHEMBL1852467 | 0.75 | SSTR4 (0.36) | SSTR4CA14 | |
| SCHEMBL24738291 | 0.75 | CA14 (0.43) | SSTR4CA14ASGR1 | |
| SCHEMBL15103109 | 0.75 | CNR2 (0.41) | CA14IL1BP2RX7RORC | |
| SCHEMBL7333606 | 0.74 | CPN1 (0.35) | SSTR4CA14 | |
| SCHEMBL503444 | 0.74 | CA14 (0.53) | SSTR4CA14ASGR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199993-B2 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150051243-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-02-19 | — | — | US | disclosed |
| US-8802698-B2 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140080855-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-2183249-B1 | 8-Azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE INC (US) | 2014-02-26 | — | — | EP | disclosed |
| US-8481563-B2 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110118306-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7902220-B2 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | Theravance, Inc, (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090062333-A1 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118306-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | SSTR4 573/4885CA14 4555/4885OPRM1 1/4885 |
| US-20150051243-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | SSTR4 573/4885CA14 4555/4885OPRM1 1/4885 |
| US-20140080855-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | SSTR4 573/4885CA14 4555/4885OPRM1 1/4885 |
| US-20090062333-A1 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | SSTR4 573/4885CA14 4555/4885OPRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.